Market Cap | 18.68M | P/E | - | EPS this Y | 14.00% | Ern Qtrly Grth | - |
Income | -23.96M | Forward P/E | - | EPS next Y | 45.00% | 50D Avg Chg | -3.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | 26.00% |
Dividend | N/A | Price/Book | 0.65 | EPS next 5Y | - | 52W High Chg | -47.00% |
Recommedations | 2.00 | Quick Ratio | 3.45 | Shares Outstanding | 15.97M | 52W Low Chg | 149.00% |
Insider Own | 6.86% | ROA | -58.01% | Shares Float | 13.89M | Beta | 2.17 |
Inst Own | 30.06% | ROE | -102.79% | Shares Shorted/Prior | 11.22K/10.78K | Price | 1.17 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 160,885 | Target Price | 3.37 |
Oper. Margin | - | Earnings Date | - | Volume | 116,110 | Change | -0.85% |
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
HC Wainwright & Co. | Buy | Mar 21, 24 |
HC Wainwright & Co. | Buy | Nov 1, 23 |
Maxim Group | Buy | Sep 11, 23 |
HC Wainwright & Co. | Neutral | Jun 6, 23 |
HC Wainwright & Co. | Neutral | Mar 23, 23 |
HC Wainwright & Co. | Buy | Feb 7, 23 |
HC Wainwright & Co. | Buy | Feb 2, 22 |
ThinkEquity | Buy | Jan 24, 22 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Lehr Martin A. | Chief Executive Offi.. Chief Executive Officer | Feb 21 | Buy | 0.8415 | 5,823 | 4,900 | 159,701 | 02/21/23 |
Lehr Martin A. | Chief Executive Offi.. Chief Executive Officer | Feb 13 | Buy | 0.8742 | 5,606 | 4,901 | 153,878 | 02/13/23 |
Lehr Martin A. | Chief Executive Offi.. Chief Executive Officer | Dec 16 | Buy | 0.7398 | 20,000 | 14,796 | 122,583 | 12/19/22 |
Minai-Azary Jennifer Lynn | Chief Financial Offi.. Chief Financial Officer | Aug 17 | Buy | 1.80 | 15,000 | 27,000 | 15,000 | 08/17/22 |
Sahmoud Tarek | Chief Medical Office.. Chief Medical Officer | Aug 16 | Buy | 1.95 | 10,000 | 19,500 | 10,000 | 08/17/22 |
Lehr Martin A. | Chief Executive Offi.. Chief Executive Officer | Oct 22 | Buy | 5 | 10,000 | 50,000 | 99,583 | 10/25/21 |